Drug-induced glomerulopathies

Expert Opinion on Drug Safety

Volumn 5, Issue 1, 2006, Pages 95-106

  Izzedine, Hassan ^a   Launay Vacher, Vincent ^a   Bourry, Edward ^a   Brocheriou, Isabelle ^a   Karie, Svetlana ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Collapsing focal segmental glomerulosclerosis (FSGS); Crescentic glomerulonephritis; Lupus nephritis; Membranous nephropathy; Minimal change disease

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APROTININ; AZLOCILLIN; BUCILLAMINE; CAPTOPRIL; CELECOXIB; CIPROFLOXACIN; DICLOFENAC; DIURETIC AGENT; ENALAPRIL; FENOPROFEN; GOLD SALT; HEAVY METAL; HLA B8 ANTIGEN; HLA DR3 ANTIGEN; ISONIAZID; LITHIUM CARBONATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENICILLAMINE; PLACEBO; PYRITINOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULINDAC; THIAMAZOLE; TIOPRONIN; UNINDEXED DRUG;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ALBUMINURIA; AMINOTRANSFERASE BLOOD LEVEL; ANCA ASSOCIATED VASCULITIS; ANEMIA; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYSTINURIA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EOSINOPHILIA; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; FOCAL GLOMERULOSCLEROSIS; GENETIC SUSCEPTIBILITY; GLOMERULOPATHY; HEMATURIA; HEMODIALYSIS; HUMAN; HYPOTHYROIDISM; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; KIDNEY INJURY; LEUKOCYTURIA; LEUKOPENIA; LIVER TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MULTIPLE MYELOMA; NEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; OLIGURIA; PLASMAPHERESIS; POLYARTERITIS NODOSA; PROTEINURIA; PYURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; NEPHROSIS, LIPOID;

EID: 30344472378     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.1.95     Document Type: Review

References (143)

1. KOREN G: The nephrotoxic potential of drugs and chemicals. Pharmacological basis and clinical relevance. Med. Toxicol. Adverse Drug Exp. (1989) 4:59-72.
2. POSPISHIL IuA: Pathohistologic and ultrastructural features of drug-induced membranous glomerulonephritis. Arkh. Patol. (1996) 58:52-56.
3. ANTONOVYCH TT: Drug-induced nephropathies. Pathol. Ann. (1984) 19(Pt 2):165-196.
4. SILVERBERG DS, KIDD EG, SHNITKA TK, ULAN RA: Gold nephropathy. A clinical and pathologic study. Arthritis Rheum. (1970) 13:812-825.
5. PELLETIER L, DRUET P: Immunologically-mediated toxin-induced renal diseases. In: Clinical Nephrotaxins. M.E. De Broe, G.A. Porter, W.M. Bennett, G.A. Verpooten (Eds.). Kluwer Academic Publishers. (1998):31-38.
6. FILLASTRE JP, VIOTTE G, MORIN JP, MOULIN B: Nephrotoxicity of antitumoral agents. Adv. Nephrol. Necker Hosp. (1988) 17:175-218.
7. FRANCIS KL, JENIS EH, HENSEN GE et al.: Gold-associated nephropathy. Arch. Pathol. Lab. Med. (1984) 108:234.
8. KATZ WA, BLODGETT RC, PIETRUSKO RG: Proteinuria in gold-treated rheumatoid arthritis. Ann. Intern. Med. (1984) 101:176.
9. TORNROTH T, SKRIFVARS B. The development and resolution of glomerular basement membrane changes associated with subepithelial immune deposits. Am. J. Pathol. (1975) 79:219-236.
10. WOOLEY PH, GRIFFIN J, PANAYI GS, BATCHELOR JR, WELSH KI, GIBSON TJ: HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N. Engl. J. Med. (1980) 303:300-302.
11. FILLASTRE JP, MERY JP, MOREL MJL, CONFER A, GODIN M: Drug-induced glomerulonephritis. Proceedings of the 8th International Congress on Nephrology, Athens, Greece, Karger, Basel (1981):49.
12. LYLE WH: Penicillamine. Clinics in Rheumatic Diseases (1979) 5:569-601.
13. CHISOLM JJ, BALTROP D: Recognition and management of children with increased lead absorption. Arch. Dis. Child. (1979) 54:249.
14. NTOSO KA, TOMASZEWSKI JE, JIMENEZ SA, NEILSON EG: Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature. Am. J. Kidney Dis. (1986) 8:159-163.
15. HILL HF: Penicillamine in rheumatoid arthritis: adverse effects. Scand. J. Rheumatol. Suppl. (1979) 28:94-99.
16. VERROUST PJ: Kinetics of immune deposits in membranous nephropathy. Kidney Int. (1989) 35:1418.
17. EMERY P, PANAYI GS, HUSTON G et al.: D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J. Rheumatol. (1984) 11:626-632.
18. HOORNTJE SJ, KALLENBERG CG, WEENING JJ et al.: Immune-complex glomerulopathy in patients treated with captopril. Lancet (1980) 1:1212-1215.
19. LEWIS EJ: Proteinuria and abnormalities of the renal glomerulus in patients with hypertension. Clin. Exp. Pharmacol. Physiol. Suppl. (1982) 7:105-115.
20. NO AUTHORS LISTED: Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Arch. Intern. Med. (1984) 144:1947-1953.
21. WEBB DJ, ATKINSON AB: Enalapril following captopril-induced nephrotic syndrome. Scott. Med. J. (1986) 31:30-32.
22. KALLENBERG CG, VAN DER LAAN S, DE ZEEUW D. Capropril and the immune system. Lancet (1981) 2:92.
23. NAGAHAMA K, MATSUSHITA H, HARA M, UBARA Y, HARA S, YAMADA A: Bucillamine induces membranous glomerulonephritis. Am. J. Kidney Dis. (2002) 39:706-712.
24. OLIVEIRA DB, FOSTER G, SAVILL J et al.: Membranous nephropathy caused by mercury-containing skin lightening cream. Postgrad. Med. J. (1987) 63:303-304.
25. MEEKS A, KEITH PR, TANNER MS: Nephrotic syndrome in two members of a family with mercury poisoning. J. Trace Elem. Electrolytes Health Dis. (1990) 4:237-239.
26. HILL GS: Drug-associated glomerulopathies. Toxicol. Pathol. (1986) 14:37-44.
27. KIBUKAMUSOKE JW, DAVIES DR, HUTT MS: Membranous nephropathy due to skin-lightening cream. Br. Med. J. (1974) 2:646-647.
28. TUBBS RR, GEPHARDT GN, MCMAHON JT et al.: Membranous glomerulonephritis associated with industrial mercury exposure: Study of pathogenetic mechanisms. Am. J. Clin. Pathol. (1982) 77:409-413.
29. BELGHITI D, PATEY O, BERRY JP et al.: Lipoid nephrosis of toxic origin: 2 cases. Presse (1986) 15:1953-1955.
30. LINDELL A, DENNEBERG T, ENESTROM S et al.: Membranous glomerulonephritis induced by 2-mercaptopropionylglycine (2-MPG). Clin. Nephrol. (1990) 34:108-115.
31. PHAN L, COULOMB F, BOUDON M et al.: Extramembranous glomerulonephritis induced by lithium. Nephrologie (1991) 12:185-187.
32. APPEL GB, D'AGATI V, BERGMAN M, PIRANI CL: Nephrotic syndrome and immune complex glomerulonephritis associated with chlorpropamide therapy. Am. J. Med. (1983) 74:337-342.
33. DANDONA P, MIER A, BOAG F, CHAPPELL M, BECKETT AG: Aprotinin induced lipohypertrophy and glomerulonephritis in an insulin dependent diabetic. Diabetes Res. (1985) 2:213-216.
34. DEN BROEDER AA, ASSMANN KJ, VAN RIEL PL, WETZELS JF: Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth. J. Med. (2003) 61:137-141.
35. MARKOWITZ GS, FALKOWITZ DC, ISOM R et al.: Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clin. Nephrol. (2003) 59:137-142.
36. CLIVE DM, STOFF JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1984) 310:563-572.
37. BLACKSHEAR JL, NAPIER JS, DAVIDMAN M, STILLMAN MT: Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Semin. Arthritis Rheum. (1985) 14:163-175.
38. ROSSERT J: Drug-induced acute interstitial nephritis. Kidney Int. (2001) 60:804-817.
39. LEVIN ML: Patterns of tubulo-interstitial damage associated with nonsteroidal. Semin. Nephrol. (1988) 8:55-61.
40. AVERBUCH SD, AUSTIN HA 3rd, SHERWIN SA, ANTONOVYCH T, BUNN PA JR, LONGO DL: Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides. N. Engl. J. Med. (1984) 310:32-35.
41. WHELTON A, WATSON AJ: Nonsteroidal anti-inflammatory drugs: effects on kidney function. In: Clinical Nephrotoxins. M.E. De Broe, G.A. Porter, W.M. Bennett, G.A. Verpooten (Eds.). Kluwer Academic Publishers (1998):203-216.
42. WHELTON A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. (1999) 106:13S-24S.
43. SANTELLA RN, RIMMER JM, MACPHERSON BR: Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am. J. Med. (1988) 84:951-954.
44. SCHOU M: Forty years of lithium treatment. Arch. Gen. Psychiatry (1997) 54:9-13.
45. ALEXANDER F, MARTIN J: Nephrotic syndrome associated with lithium therapy. Clin. Nephrol. (1981) 15:267-271.
46. RICHMAN AV, MASCO HL, RIFKIN SI, ACHARYA MK: Minimal-change disease and the nephrotic syndrome associated with lithium therapy. Ann. Intern. Med. (1980) 92:70-72.
47. TAMM VKK, GREEN J, SCHWIEGER J, COHEN AH: Nephrotic syndrome and renal insufficiency associated with lithium therapy. Am. J. Kidney Dis. (1996) 27:715-720.
48. STAHLMANN R, LODE H: Safety overview: toxicity, adverse effects, and drug interactions. In: The Quinolones. Andreoli VT, (Ed). London: Academic Press. (1988):201-233.
49. JOHNSON PR, LIU YIN JA, TOOTH JA: A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J. Antimicrob. Chemother. (1992) 30:203-214.
50. ARCIERI G, GRIFFITH E, GRUENWALDT G et al.: Ciprofloxacin: an update on clinical experience. Am. J. Med. (1987) 82:381-386.
51. WOLSON JS, HOOPER DC. Overview of fluoroquinolone safety. Am. J. Med. (1991) 91:153S-161S.
52. LO WK, ROLSTON KV, RUBENSTEIN EB, BODEY GP: Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch. Intern. Med. (1993) 153:1258-1262.
53. HANSON B, D'HONDT A, DEPIERREUX M, LUSTMAN F: Nephrotic syndrome after norfloxacin. Nephron (1996) 74:446.
54. HESTIN D, HANESSE B, FRIMAT L, RENAUDIN JM, NETTER P, KESSLER M: Norfloxacin-induced nephrotic syndrome. Lancet (1995) 345:732-733.
55. HESLAN JM, BRANELLEC AI, PILATTE Y, LANG P, LAGRUE G: Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin. Exp. Immunol. (1991) 86:157-162.
56. FORSGREN A, BREDBERG A, RIESBECK K: New quinolones: in vitro effects as a potential source of clinical toxicity. Rev. Infect. Dis. (1987) 11:1382-1389.
57. LECOULES S, DUVIC C, HERODY M, NEDELEC G: Tiopronin-induced nephrotic syndrome with minimal glomerular lesions. Presse Med. (1999) 28:273-275.
58. ALPER AB Jr, MELEG-SMITH S, KRANE NK: Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am. J. Kidney Dis. (2002) 40:1086-1090.
59. D'AGATI V: Pathologic classification of focal segmental glomerulosclerosis. Semin. Nephrol. (2003) 23:117-1134.
60. BERENSON JR, LICHTENSTEIN A, PORTER L et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. (1996) 334:488-493.
61. HORTOBAGYI GN, THERIAULT RL, LIPTON A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol. (1998) 16:2038-2044.
62. MARKOWITZ GS, APPEL GB, FINE PL et al.: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J. Am. Soc. Nephrol. (2001) 12:1164-1172.
63. LOCKRIDGE L, PAPAC RJ, PERAZELLA MA: Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis. Am. J. Kidney Dis. (2002) 40:E2.
64. DESIKAN R, VEKSLER Y, RAZA S et al.: Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br. J. Haematol. (2002) 119:496-469.
65. VAN BEEK E, PIETERMAN E, COHEN L, LOWIK C, PAPAPOULOS S: Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun. (1999) 255:491-494.
66. BERGSTROM JD, BOSTEDOR RG, MASARACHIA PJ, RESZKA AA, RODAN G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. (2000) 373:231-241.
67. COXON FP, HELFRICH MH, VAN'T HOF R et al.: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. (2000) 15:1467-1476.
68. SCHREINER A, WALDHERR R, ROHMEISS P, HEWER W: Focal segmental glomerulosclerosis and lithium treatment. Am. J. Psychiatry (2000) 157:834.
69. MARKOWITZ GS, RADHAKRISHNAN J, KAMBHAM N, VALERI AM, HINES WH, D'AGATI VD: Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J. Am. Soc. Nephrol. (2000) 11:1439-1448.
70. WALKER RG, BENNETT WM, DAVIES BM, KINCAID-SMITH P: Structural and functional effects of long-term lithium therapy. Kidney Int. Suppl. (1982) 11:S13-S19.
71. CAMBRIDGE G, WALLACE H, BERNSTEIN RM, LEAKER B: Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Br. J. Rheumatol. (1994) 33:109-114.
72. VOGT BA, KIM Y, JENNETTE JC, FALK RJ, BURKE BA, SINAIKO A: Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J. Pediatr. (1994) 124:986-988.
73. NASSBERGER L, JOHANSSON AC, BJORCK S, SJOHOLM AG: Antibodies to neutrophil granulocyte myeloperoxidase and elastase: Autoimmune responses in glomerulonephritis due to hydralazine treatment. J. Intern. Med. (1991) 229:261-265.
74. MATHIESON PW, PEAT DS, SHORT A, WATTS RA: Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine. Nephrol. Dial. Transplant. (1996) 11:863-836.
75. JONES BF, MAJOR GA: Crescentic glomerulonephritis in a patient taking penicillamine associated with antineutrophil cytoplasmic antibody. Clin. Nephrol. (1992) 38:293.
76. ELKAYAM O, YARON M, CASPI D: Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann. Rheum. Dis. (1996) 55:769-771.
77. SCHAFFER JV, DAVIDSON DM, MCNIFF JM, BOLOGNIA JL: Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J. Am. Acad. Dermatol. (2001) 44:198-206.
78. DUNPHY J, OLIVER M, RANDS AL, LOVELL CR, MCHUGH NJ: Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br. J. Dermatol. (2000) 142:461-467.
79. YOUNG JL JR, BOSWELL RB, NIES AS: Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch. Intern. Med. (1974) 134:553-558.
80. PARKER CW: Drug therapy. Drug allergy (second of three parts). N. Engl. J. Med. (1975) 292:732-736.
81. WOOLEY PH, GRIFFIN JK, PANAYI GS et al.: HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N. Engl. J. Med. (1980) 303:300.
82. ADU NTOSO K, TOMAZEWSKI JE, JIMENEZ SA et al.: Penicillamine-induced rapidly progressive glomerulonephritis in patients with primary systemic sclerosis: Successful treatment of two patients and a review of the literature. Am. J. Kidney Dis. (1986) 8:159.
83. HALL OL: The natural course of gold and penicillamine nephropathy: A longterm study of 54 patients. Adv. Exp. Biol. (1989) 252:247-256.
84. GABOW PA, LACHER JW, NEFF TA: Tubulointerstitial and glomerular nephritis associated with rifampin. Report of a case. JAMA (1976) 235:2517-2518.
85. NEUGARTEN J, GALLO GR, BALDWIN DS: Rifampin-induced nephrotic syndrome and acute interstitial nephritis. Am. J. Nephrol. (1983) 3:38-42.
86. HIRSCH DJ, BIA FJ, KASHGARIAN M, BIA MJ: Rapidly progressive glomerulonephritis during antituberculous therapy. Am. J. Nephrol. (1983) 3:7-10.
87. MURRAY AN, CASSIDY MJ, TEMPLECAMP C: Rapidly progressive glomerulonephritis associated with rifampicin therapy for pulmonary tuberculosis. Nephron (1987) 46:373-376.
88. OGATA H, KUBO M, TAMAKI K, HIRAKATA H, OKUDA S, FUJISHIMA M: Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis. Nephron (1998) 78:319-322.
89. YOSHIOKA K, SATAKE N, KASAMATSU Y, NAKAMURA Y, SHIKATA N: Rapidly progressive glomerulonephritis due to rifampicin therapy. Nephron (2002) 90:116-118.
90. DE VRIESE AS, ROBBRECHT DL, VANHOLDER RC, VOGELAERS DP, LAMEIRE NH: Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am. J. Kidney Dis. (1998) 31:108-115.
91. AMERICAN ACADEMY OF PEDIATRICS: Committee on Infectious Diseases: Screening for tuberculosis in infants and children. Pediatrics (1994) 93:131-134.
92. STRATTON MA: Drug-induced systemic lupus erythematosus. Clin. Pharm. (1985) 4:657-663.
93. BRIK R, MAGEN D, BEN-YZHAK O, GRIN J: Isoniazid-induced crescentic glomerulonephritis in a child with a positive tuberculin skin test. Am. J. Nephrol. (1998) 18:430-432.
94. SETHI S, SAHANI M, OEI LS: ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. Am. J. Kidney Dis. (2003) 42:E27-E31.
95. YUASA S, HASHIMOTO M, YURA T et al.: Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy. Nephrology (1996) 3:701-703.
96. DOLMAN KM, GANS RO, VERVAAT TJ et al.: Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet (1993) 342:651-652.
97. PRASAD GV, BASTACKY S, JOHNSON JP: Propylthiouracil-induced diffuse proliferative lupus nephritis: Review of immunological complications. J. Am. Soc. Nephrol. (1997) 8:1205-1210.
98. COLAKOVSKI H, LORBER DL: Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis. Endocr. Pract. (2001) 7:37-39.
99. KYNDT X, DUCQ P, BRIDOUX F et al.: Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D. Presse Med. (1999) 28:67-70.
100. SILVERMAN SH, GRIBETZ D, RAUSEN AR: Nephrotic syndrome associated with ethosuccimide. Am. J. Dis. Child. (1978) 132:99.
101. BAR-KHAYIM Y, TEPLITZ C, GARELLA S, CHAZAN JA: Trimethadione (Tridione)-induced nephrotic syndrome: A report of a case with unique ultrastructural renal pathology. Am. J. Med. (1973) 54:272-280.
102. HEYMANN W: Nephrotic syndrome after use of trimethadione and paramethadione in petit mal. JAMA (1967) 202:893-894.
103. SNEAD C, SIEGEL N, HAYSLETT J: Generalized lymphadenopathy and nephrotic syndrome as a manifestation of mephenytoin (mesantoin) toxicity. Pediatrics (1976) 57:98-101.
104. PARKER MG, ATKINS MB, UCCI AA, LEVEY AS: Rapidly progressive glomerulonephritis after immunotherapy for cancer. J. Am. Soc. Nephrol. (1995) 5:1740-1744.
105. TROLLIET P, DIJOUD F, COTTE L et al.: Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am. J. Nephrol. (1995) 15:256-259.
106. FAKHRO AM, RITCHIE RF, LOWN B: Lupus-like syndrome induced by procainamide. Am. J. Cardiol. (1967) 20:367-373.
107. HOPE RR, BATES LA: The frequency of procainamide-induced systemic lupus erythematosus. Med. J. Aust. (1972) 2:298-303.
108. BICKER JN, BUECHNER HA, HOOD BJ et al.: Hypersensitivity reaction to antituberculous drugs with hepatitis, lupus phenomenon and myocardial infarction. N. Engl. J. Med. (1961) 265:131-132.
109. BENTON JW, TYNES B, REGISTER HB Jr et al.: Systemic lupus erythematous occurring during anticonvulsivant drug therapy. JAMA (1962) 180:115-118.
110. SHEIKH TK, CHARRON RC, KATZ A: Renal manifestations of drug-induced systemic lupus erythematosus. Am. J. Clin. Pathol. (1981) 75:755-762.
111. LING BN, BOURKE E, CAMPBELL WG Jr, DELANEY VB: Naproxen-induced nephropathy in systemic lupus erythematosus. Nephron (1990) 54:249-255.
112. ALARCON-SEGOVIA D, WAKIM KG, WORTHINGTON JW, WARD LE: Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine (Baltimore) (1967) 46:1-33
113. CASTELMAN B, NCNEELY BV: Case records of the Massachusetts General Hospital. N. Engl. J. Med. (1968) 278:1167-1173.
114. DAMMIN GJ, NORA JR, REARDAN JB: Hydralazine reaction: case with LE cells, antemortem and postmortem, and pulmonary, renal, splenic and muscular lesions of disseminated lupus eryhtematous. J. Lab. Clin. Med. (1955) 46:806.
115. GUNTHER R, ASAMER H, DITTRICH P: The reversible procaine amide-induced lupus-erythromatosus syndrome. Dtsch. Med. Wochenschr. (1969) 94:2338-2342.
116. RALLISON ML, CARLISLE JW, LEE RE Jr, VERNIER RL, GOOD RA: Lupus erythematosus and Stevens-Johnson syndrome. Occurrence as reactions to anticonvulsant medication. Am. J. Dis. Child. (1961) 101:725-738.
117. WHITTINGHAM S, MACKAY IR: Systemic lupus erythematosus induced by procaine amide. Australas. Ann. Med. (1970) 19:358-361.
118. WHITTLE TS Jr, AINSWORTH SK: Procainamide-induced systemic lupus erythematosus. Renal involvement with deposition of immune complexes. Arch. Pathol. Lab. Med. (1976) 100:469-474.
119. SWAINSON CP, THOMSON D, SHORT AI, WINNEY RJ: Plasma exchange in the successful treatment of drug-induced renal disease. Nephron (1982) 30:244-2449.
120. FRITZLER MJ: Drugs recently associated with lupus syndromes. Lupus (1994) 3:455-459.
121. SACCHI S, KANTARJIAN H, O'BRIEN S, COHEN PR, PIERCE S, TALPAZ M: Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J. Clin. Oncol. (1995) 13:2401-2407.
122. RONNBLOM LE, ALM GV, OBERG KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. (1991) 115:178-183.
123. OHTA S, YOKOYAMA H, WADA T et al.: Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am. J. Kidney Dis. (1999) 33:1040-1048.
124. SCHOMBURG A, KIRCHNER H, ATZPODIEN J: Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy. J. Cancer Res. Clin. Oncol. (1993) 119:745-755.
125. JONES GJ, ITRI LM: Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer (1986) 57:1709-1715.
126. LEDERER E, TRUONG L: Unusual glomerular lesion in a patient receiving long-term interferon alpha. Am. J. Kidney Dis. (1992) 20:516-518.
127. WILLSON RA: Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J. Clin. Gastroenterol. (2002) 35:89-92.
128. JADOUL M, PIESSEVAUX H, FERRANT A, COSYNS JP, VAN YPERSELE DE STRIHOU C: Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol. Dial. Transplant. (1995) 10:111-113.
129. RETTMAR K, KIENAST J, VAN DE LOO J: Minimal change glomerulonephritis with reversible proteinuria during interferon alpha 2a therapy for chronic myeloid leukemia. Am. J. Hematol. (1995); 49:355-356.
130. SELBY P, KOHN J, RAYMOND J, JUDSON I, MCELWAIN T: Nephrotic syndrome during treatment with interferon. Br. Med. J. (Clin. Res. Ed.) (1985) 290:1180.
131. TRAYNOR A, KUZEL T, SAMUELSON E, KANWAR Y: Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma. Nephron (1994) 67:94-100.
132. CORONEOS E, PETRUSEVSKA G, VARGHESE F, TRUONG LD: Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am. J. Kidney Dis. (1996) 28:888-892.
133. SHAH M, JENIS EH, MOOKERJEE BK et al.: Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer (1998) 83:1938-1946.
134. MOREL-MAROGER L, SLOPER JC, VINTER J, WOODROW D, GRESSER I: An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab. Invest. (1978) 39:513-522.
135. DI BISCEGLIE AM, MARTIN P, KASSIANIDES C et al.: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. (1989) 321:1506-1510.
136. DAVIS GL, BALART LA, SCHIFF ER et al.: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. (1989) 321:1501-1506.
137. NIEDERAU C, HEINTGES T, LANGE S et al.: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. (1996) 334:1422-1427.
138. WAGSTAFF AJ, BRYSON HM: Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs (1994) 48:199-226.
139. JACOBSON MA, MILLS J: Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann. Intern. Med. (1988) 108:585-594.
140. PALESTINE AG, POLIS MA, DE SMET MD et al.: A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. (1991) 115:665-673.
141. DERAY G, MARTINEZ F, KATLAMA C et al.: Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol. (1989) 9:316-321.
142. JACOBSON MA: Review of the toxicities of foscarnet. J. Acquir. Immune Defic. Syndr. (1992) 5(Suppl. 1):S11-S17.
143. BEAUFILS H, DERAY G, KATLAMA C et al.: Foscarnet and crystals in glomerular capillary lumens. Lancet (1990) 336:755.